<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="3" ids="16335">Adenosine</z:chebi> receptors (ARs), the major targets of <z:chebi fb="111" ids="27732">caffeine</z:chebi> and <z:chebi fb="1" ids="28177">theophylline</z:chebi>, comprise four receptor subtypes designated as A(1), A(2A), A(2B) and A(3) </plain></SENT>
<SENT sid="1" pm="."><plain>Over a dozen AR <z:chebi fb="4" ids="48705">agonists</z:chebi> are currently in clinical trials for various conditions, including <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo>, neuropathic pain, myocardial perfusion imaging, <z:mp ids='MP_0004120'>cardiac ischemia</z:mp>, <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="3" ids="16335">Adenosine</z:chebi> (nonselective), regadenoson (A(2A)) and <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> (act indirectly via ARs) have received regulatory approval for clinical use </plain></SENT>
<SENT sid="3" pm="."><plain>The present editorial will give a brief update on the current status of AR <z:chebi fb="4" ids="48705">agonists</z:chebi> in clinical trials </plain></SENT>
</text></document>